SFSIG
TOVX icon

San Francisco Sentry Investment Group’s Theriva Biologics TOVX Stock Holding History

San Francisco Sentry Investment Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6
Closed -$17K – 869
2018
Q1 		$17K Buy
6
+1
+20% +$3.8K ﹤0.01% 616
2017
Q4 		$24K Hold
5
– – 0.01% 543
2017
Q3 		$43K Hold
5
– – 0.01% 457
2017
Q2 		$23K Buy
5
+2
+67% +$9.96K 0.01% 443
2017
Q1 		$16K Buy
3
+1
+50% +$6.98K 0.01% 196
2016
Q4 		$16K Buy
2
+1
+100% +$10.3K 0.01% 186
2016
Q3 		$21K Buy
+1
New +$15K 0.01% 166

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

San Francisco Sentry Investment Group's TOVX Position: Q2 2018 in Review

San Francisco Sentry Investment Group sold out of Theriva Biologics (TOVX) in Q2 2018, closing a stake of 6 shares — an estimated $17K sold.

San Francisco Sentry Investment Group first reported a position in TOVX in Q3 2016 and held it in 7 quarters. The position peaked at $43K in Q3 2017. 46 funds tracked by Wall St. Rank hold TOVX as of Q2 2018.

  • San Francisco Sentry Investment Group reported no remaining Theriva Biologics position as of Q2 2018 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 6 Theriva Biologics shares in Q2 2018, an estimated $17K.
  • San Francisco Sentry Investment Group first reported a position in Theriva Biologics in Q3 2016 and held it in 7 quarters.
  • San Francisco Sentry Investment Group's Theriva Biologics position peaked at $43K in Q3 2017.
  • 46 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2018.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2018, filed 6 Aug 2018.